Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase III drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Efruxifermin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Efruxifermin overview

Efruxifermin (AKR-001) is under development for the treatment of non-alcoholic steatohepatitis (NASH), type 2 diabetes and cirrhosis due to NASH. The drug candidate is a long-acting fibroblast growth factor 21 (FGF21) analog. It is a fusion protein obtained by the fusion of Fc domain of human IgG1 to the N-terminus of human mature FGF21 via a linker peptide. The drug candidate acts by targeting fibroblast growth factor receptors 1, 2, 3. It is administered through subcutaneous route. It was also under development for obesity.

Akero Therapeutics overview

Akero Therapeutics is a clinical-stage company. It is engaged in the development of transformational treatments for non-alcoholic steatohepatitis (NASH), which is a serious liver disease without any approved therapies. Akero’s lead product candidate, efruxifermin (EFX), is an engineered Fc-FGF21 fusion protein. EFX is engineered to mimic an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. It is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. It also develops medicines for the treatment of metabolic diseases. The company is funded by Atlas Venture, ATP, venBio Partners, and Versant Ventures. The company operates through offices in Massachusetts and California. Akero Therapeutics is headquartered in San Francisco, California, US.

For a complete picture of Efruxifermin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.